WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Across the recent three months, 11 analysts have shared their insights on WAVE Life Sciences (NASDAQ:WVE), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 5 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.27, along with a high estimate of $52.00 and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 24.23% from the previous average price target of $30.00.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $52.00 | $43.00 |
| Yun Zhong | Wedbush | Raises | Outperform | $35.00 | $33.00 |
| Andrew S. Fein | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| Benjamin Burnett | Wells Fargo | Lowers | Overweight | $27.00 | $29.00 |
| Steve Seedhouse | Cantor Fitzgerald | Raises | Overweight | $41.00 | $34.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $43.00 | $40.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $30.00 | $22.00 |
| Cheng Li | Oppenheimer | Raises | Outperform | $32.00 | $24.00 |
| Joon Lee | Truist Securities | Raises | Buy | $50.00 | $36.00 |
| Madison El-Saadi | B. Riley Securities | Raises | Buy | $37.00 | $19.00 |
| Yun Zhong | Wedbush | Raises | Outperform | $33.00 | $20.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to WAVE Life Sciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WAVE Life Sciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for WAVE Life Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into WAVE Life Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on WAVE Life Sciences analyst ratings.
All You Need to Know About WAVE Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Key Indicators: WAVE Life Sciences's Financial Health
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, WAVE Life Sciences faced challenges, resulting in a decline of approximately -79.41% in revenue growth as of 31 December, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -308.37%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -16.54%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.09%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: WAVE Life Sciences's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.